biostudies-literatureXu YScience and Technology Commission of Shanghai MunicipalityNational Natural Science Foundation of ChinaNCI NIH HHSNational Institutes of Health282-291.e4https://www.ebi.ac.uk/biostudies/studies/S-EPMC12364601biostudies-literatureUnknown32(3)The CD93/IGFBP7 axis proteins are key factors expressed in endothelial cells (EC) that mediate EC angiogenesis and migration. Their upregulation contributes to tumor vascular abnormality and a blockade of this interaction promotes a favorable tumor microenvironment for therapeutic interventions. However, the interactions of these proteins with each other remain unclear. In this study, we determined a partial structure of the human CD93-IGFBP7 complex comprising the EGF₁ domain of CD93 and the IB domain of IGFBP7. Mutagenesis studies confirmed interactions and specificities. Cellular and mouse tumor studies demonstrated the physiological relevance of the CD93-IGFBP7 interaction in EC angiogenesis. Our study provides leads for the development of therapeutic agents to precisely disStructure (London, England : 1993)Structural insight into CD93 recognition by IGFBP7.PMC12364601R01 CA269644R01 CA27939832171215R01CA279398R01CA269644R01CA258302R01 CA25830221JC1402400Zhu YSun YSong GXu YfalseStructural insight into CD93 recognition by IGFBP7.The CD93/IGFBP7 axis proteins are key factors expressed in endothelial cells (EC) that mediate EC angiogenesis and migration. Their upregulation contributes to tumor vascular abnormality and a blockade of this interaction promotes a favorable tumor microenvironment for therapeutic interventions. However, the interactions of these proteins with each other remain unclear. In this study, we determined a partial structure of the human CD93-IGFBP7 complex comprising the EGF₁ domain of CD93 and the IB domain of IGFBP7. Mutagenesis studies confirmed interactions and specificities. Cellular and mouse tumor studies demonstrated the physiological relevance of the CD93-IGFBP7 interaction in EC angiogenesis. Our study provides leads for the development of therapeutic agents to precisely dis2024-01-01T00:00:00Z2024 Mar2026-05-29T14:23:41.474Z2026-04-08T05:03:23.057ZS-EPMC123646013821818010.1016/j.str.2023.12.011